Welcome to our dedicated page for Waldencast plc SEC filings (Ticker: WALD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Waldencast plc filings document the company's foreign-issuer reporting for a beauty and wellness platform with Obagi Medical and Milk Makeup as operating brands. Form 6-K reports furnish financial results, interim consolidated financial statements, earnings-date notices, and business updates covering skincare, cosmetics, medical aesthetics, distribution, operating expenses, and brand performance.
The filing record also covers annual general meeting voting, director re-appointments, auditor ratification, credit-facility agreements, trademark transfer and coexistence agreements involving the Obagi mark in Japan, and registration-statement incorporation references. Other disclosures address the completed SEC investigation connected to prior financial restatement matters and material weaknesses in internal control over financial reporting.
Waldencast plc reported a difficult 2025, with heavy losses despite stable sales. Full-year net revenue was $272.1 million, down 0.7% from 2024, while Adjusted EBITDA fell to $16.1 million from $40.3 million. Net loss widened sharply to $248.1 million, driven mainly by goodwill impairments at Obagi Medical and Milk Makeup, higher financing costs and depreciation and amortization.
Q4 2025 net revenue was $72.0 million, flat year over year, but Adjusted EBITDA dropped to $6.6 million from $11.2 million as gross margins contracted and the company invested ahead of 2026 product launches, including Obagi injectables. Obagi Medical grew revenue 8.3% for the year, while Milk Makeup net revenue fell 11.4% amid softer international demand.
Waldencast worked to strengthen its balance sheet, selling the Obagi Japan trademark for $82.5 million and using $77.5 million to repay debt, and replacing its facility with a new $225 million three-year credit line. Net debt improved to $121.7 million as of December 31, 2025, from $154.2 million a year earlier, with cash rising to $30.4 million. The Board is running a broad strategic review and is not providing a 2026 outlook.
Waldencast plc, a Jersey-incorporated beauty company owning the Obagi Medical and Milk Makeup brands, files its annual report detailing a complex risk profile. The business is organized into two reporting units and prepares U.S. dollar financials under U.S. GAAP.
The company is conducting a broad strategic review announced in August 2025, with no assurance that any transaction will occur or create shareholder value. It records substantial non-cash impairment charges of $132.1 million for Obagi Medical and $20.0 million for Milk Makeup, leaving goodwill and other intangibles at about 81% of total assets and highly sensitive to further write-downs.
Liquidity and leverage are key concerns, including covenant and warrant obligations under the Lumina Credit Agreement that could lead to dilution or forced asset sales. Waldencast discloses ongoing material weaknesses in internal control over financial reporting, an SEC investigation related to prior restatements, and upcoming Sarbanes-Oxley Section 404 auditor attestation requirements, all of which add regulatory and execution risk.
Waldencast plc announced that it will release its Fourth Quarter and Fiscal Year 2025 earnings in a press release on March 13, 2026, before the U.S. market opens. The company does not plan to host a conference call to discuss the results, citing its ongoing strategic review.
Waldencast is a global multi-brand beauty and wellness platform founded by Michel Brousset and Hind Sebti, built around developing, acquiring, and scaling conscious, high-growth, purpose-driven brands such as Obagi Medical and Milk Makeup.
Waldencast plc reported the results of its annual general meeting held on January 14, 2026. Shareholders present in person or by proxy represented 92,255,519 ordinary shares, equal to 72.05% of the outstanding ordinary shares as of the December 9, 2025 record date.
Three Class III directors were re-appointed to serve until the general meeting to be held in 2028. Votes in favor were 91,182,921 for Michel Brousset, 89,332,770 for Felipe Dutra, and 79,174,145 for Simon Dai, with the remainder cast as against or abstain for each. Shareholders also ratified the selection of Deloitte & Touche LLP as independent registered public accounting firm until the conclusion of the next annual general meeting, with 89,968,656 votes for, 25,639 against, and 2,261,224 abstentions.
Waldencast plc is registering up to 9,819,000 Class A ordinary shares for resale by existing holders, not for a new capital raise. These shares are contingent consideration from the Novaestiq acquisition and relate to exclusive U.S. commercialization rights for saypha-branded cosmetic filler products. The package includes 3,273,000 shares already earned upon FDA approval of Obagi saypha MagIQ injectable hyaluronic acid gel and up to 6,546,000 additional shares tied to future sales milestones.
The sellers, primarily Croma-Pharma GmbH and NVQ Investors Holding, LLC, may sell their shares over time under this shelf prospectus, while Waldencast receives no proceeds from these resales but covers registration expenses. The Novaestiq deal also includes $3.0 million in cash and a 5.0% share of net sales of Phase 1 products above $120.0 million, plus lock-up schedules that stagger when milestone shares can be sold, which may influence future trading volumes in Waldencast stock.
Waldencast plc has furnished a Form 6-K announcing that it has released its Q2 2025 financial results and a Q3 2025 trading update. The company reports on business and financial performance for the three and six months ended June 30, 2025, and provides a trading update for the three months ended September 30, 2025, via a press release attached as Exhibit 99.1. The Form 6-K states that this information is being furnished rather than filed and will only be incorporated by reference into other filings if specifically referenced.
Waldencast plc filed a Form 6-K to provide its unaudited interim consolidated financial statements for the six months ended June 30, 2025. These H1 2025 interim financials are furnished as Exhibit 99.1.
The filing also lists several material agreements as exhibits, including a Credit Agreement dated November 14, 2025 involving Milk Makeup LLC, Obagi Cosmeceuticals LLC, Waldencast Partners plc as parent guarantor, various lenders and LSSF II Offshore Investments, LP as administrative agent. In addition, it includes a Trademark Transfer Agreement and a Trademark Coexistence Agreement, both dated November 13, 2025, between Rohto Pharmaceutical Co., Ltd. and Obagi Cosmeceuticals LLC.
The report and its exhibits are incorporated by reference into Waldencast’s existing registration statements on Form S-8 and Form F-3, meaning these interim financials and agreements now form part of those shelf and incentive plan disclosures.
Waldencast plc reported updates via a Form 6-K, noting the sale of its rights to the “Obagi” trademark in Japan and the entry into a new credit facility. The company characterized these steps as strengthening its balance sheet.
A press release dated November 14, 2025 is attached as Exhibit 99.1 for further details. The information in this report, including the exhibit, is designated as not “filed” under Section 18 of the Exchange Act.